Publications / Posters :: ContraFect Corporation (CFRX)

Publications / Posters

Technology

Home
Technology
Publications / Posters

Publications

Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Antimicrobial Agents & Chemotherapy, June 2021, Volume 65, Issue 6.

Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model

Journal of Antimicrobial Chemotherapy, July 5, 2021.

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity

Journal of Clinical Microbiology, July 2021, Volume 59, Issue 7

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Antimicrobial Agents & Chemotherapy, July 2021, Volume 65, Issue 7

Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301)

Frontiers in Medicine, May 2021, Volume 8, Article 550853

Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

The Journal of Clinical Investigation, Volume 130, Issue 7, July 1, 2020

Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography

Antimicrobial Agents & Chemotherapy, July 2020, Volume 64, Issue 7

Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model

Antimicrobial Agents & Chemotherapy, March 2020, Volume 64, Issue 3

Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

Antimicrobial Agents & Chemotherapy, February 2020, Volume 64, Issue 2

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Antimicrobial Agents & Chemotherapy, October 2019, Volume 63, Issue 10

Posters

Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans

Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans

Presented at North American Cystic Fibrosis Conference 2021, November 2, 2021

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets

Presented at ID Week 2021, September 29, 2021

Amurin Peptides: New Direct Lytic Agents (DLAs) with Broad Spectrum Antimicrobial Activity Against Gram-negative (GN) ESKAPE Pathogens

Presented at World Microbe, June 2021

Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens

Presented at World Microbe, June 2021

Lysin CF-370 In Vivo Efficacy Against a Carbapenem-Resistant Pseudomonas aeruginosa in a Rabbit Infective Endocarditis Model

Presented at World Microbe, June 2021

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models

Presented at ID Week 2019, October 4, 2019

Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Presented at ID Week 2019, October 3, 2019

Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires

Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires

Presented at ID Week 2019, October 3, 2019

Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)

Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)

Presented at ID Week 2019, October 3, 2019

Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection

Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection

Presented at ASM-ESCMID 2019, September 4, 2019

1
2
3
4
5
Next »